IONS Stock Recent News

Ionis (IONS) incurs a narrower-than-expected fourth-quarter loss. Sales beat estimates.

The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $0.37 per share a year ago.

FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.

Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Webcast scheduled for Wednesday, February 21 at 11:30 a.m. Eastern Time CARLSBAD, Calif.

Ionis (IONS) reports positive phase III study results, which show that treatment with donidalorsen achieved a statistically significant reduction in HAE attacks.

Heading into 2024, the future of the U.S. economy remains uncertain, with conflicting predictions about the possibility of a recession. While some experts anticipate a soft landing, others predict a mild recession starting in the second quarter.